had a slightly higher incidence of facial skin problems than those with oily skin. Changes in the facial microbiome might partly explain the skin problems caused by long-term mask wearing.

**Funding source**

This study was supported by grants from the National Natural Science Foundation of China (81672005, 81001271), the Mega-Project of National Science and Technology for the 12th and 13th Five-Year Plans of China (2018ZX10715-014-002, 2014ZX10004008, 2013ZX10004901, 2013ZX10004904 and 2011ZX10004-901), the Key Joint Project for the Data Center of the National Natural Science Foundation of China (U1611264) and the Fundamental Research Funds for the Central Universities (2017FZA7004).

**Conflict of interest**

All authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.

**References**

1. WHO. WHO Coronavirus Disease (COVID-19) Dashboard. 2020.
2. Gostin LO, Salmon DA. The dual epidemics of COVID-19 and Influenza: 1 WHO. WHO Coronavirus Disease (COVID-19) Dashboard. 2020. inﬂuence the work reported in this paper.

C. Huang, 1 Q. Sun, 2 D. Jiang, 1 X. Zhang, 1 C. Chen, 1 D. Yan, 1 X. Liu, 1 Y. Zhou, 1 C. Ding, 1 L. Lan, 1 J. Wu, 1 L. Li, 1∗, A. Li, 3,4∗, X. Liu, 2∗, S. Yang 1∗.

1 State Key Laboratory for Diagnosis and Treatment of Infectious Diseases, National Clinical Research Center for Infectious Diseases, Collaborative Innovation Center for Diagnosis and Treatment of Infectious Diseases, The First Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou, China, 2 Department of Dermatology, The First Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou, China, 3 Physician Health Center, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, China, 4 Department of Henan Gene Hospital, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, China.

∗Correspondence: S. Yang, X. Liu, A. Li and L. Li. E-mail: yangshigui@zju.edu.cn (S.Y.); hzlxiaoyan@zju.edu.cn (X.L.); lia@zju.edu.cn (A.L.); liji@zju.edu.cn (L.L.)

C. Huang, Q. Sun contributed equally to this study.

**Three cases of vesiculobullous non-IgE-mediated cutaneous reactions to tozinameran (Pfizer-BioNTech COVID-19 vaccine)**

Dear Editor,

There is a global uptake of vaccination against coronavirus disease 2019 (COVID-19). The Phase III trial of tozinameran, a ribonucleic acid (RNA) vaccine, demonstrated a risk of anaphylaxis at 11.1 cases per million doses. 1 Little is known regarding various non-IgE-mediated cutaneous reactions arising from the use of these vaccines. We report three cases of non-IgE-mediated cutaneous reactions following tozinameran administration, in a tertiary hospital in Singapore.

A 51-year-old gentleman developed deep-seated vesicles over his palms 1 day after administration of the second dose of tozinameran. Examination revealed scattered deep vesicles over bilateral palms, with focal desquamation (Fig. 1a,b). He was diagnosed with acute dyshidrotic eczema and treated with topical betamethasone dipropionate ointment.

A 70-year-old woman was admitted to the hospital for an acute flare of bullous pemphigoid 2 weeks following administration of the first dose of tozinameran. She had a known history of biopsy-proven bullous pemphigoid, which was controlled on tapering, low-dose prednisolone. Other drug and infective histories were unremarkable. Inpatient admission was required. Treatment consisted of prednisolone dose escalation to 0.5 mg/kg/day and application of clobetasol 0.05% cream.

Three cases of non-allergic cutaneous reactions consisting of vesiculobullous eruptions demonstrate varying degrees of severity. A case series of 12 patients with delayed local reactions to mRNA-1273 vaccine described an isolated patient developing papules over the palms 4 days after receiving the vaccine. 2 Eczema flares following vaccination for mumps, measles and rubella have been reported. 3 The pathomechanism of MMR-vaccine aggravating eczema was postulated to be that of increased interleukin-4 levels following infection by the live attenuated virions. Vaccinations may instigate a vigorous host immune response, thereby dysregulating the delicate Th1 and Th2
lymphocytic balance in these atopic individuals. The mechanism for RNA vaccine inducing vesicular eczema remains unknown. Drug-induced bullous pemphigoid remains incompletely understood.\(^4\) The pathomechanistic concept of molecular mimicry with the RNA vaccine is postulated, with SARS-CoV-2 spike proteins produced leading to activation of CD4\(^+\) T cells and initiation or rekindling of the autoimmune cascade. Bullous pemphigoid following vaccinations usually has a short latency of days.\(^5\)

**Figure 1** (a) Erythematous vesicles on bilateral palms. (b) Deep-seated tense vesicles on the palmar aspect.

**Figure 2** (a) Extensive erythematous plaques with crops of non-follicular pustules over the trunk and limbs of this patient with AGEP. (b) Non-follicular pustules on an erythematous plaque.
More than 90% of cases of AGEP are drug-induced. A case series of childhood AGEP reported 2 cases of vaccine-related AGEP,7 while a pregnant woman of 10-week gestation developed AGEP 1 day after influenza vaccination.8 Tozinameran consists of lipid and mRNA nanoparticles. AGEP may be induced via the RNA molecule, lipid vehicle or the eventual proteins arising from the translation of RNA. The propensity for components of the RNA vaccine to induce non-allergic cutaneous reactions remains insufficiently characterized. Preliminary case series have documented delayed large local reactions, termed ‘COVID arm’, and various other reactions in a registry-based report of 414 cases.9 These delayed cutaneous manifestations may be related to the host immune response instead of true vaccine allergies.

We opine that most delayed, mild non-IgE-mediated cutaneous reactions do not contraindicate further doses of the same vaccine, as these reactions are often transient and self-limiting, where the benefits of a completed vaccination schedule outweigh the potential morbidity following such reactions. Knowledge of both allergic and non-allergic cutaneous reactions to various COVID-19 vaccines is useful in the current mass vaccination exercises worldwide.

Consent for publication
This manuscript has not been published and is not under consideration for publication elsewhere.

Acknowledgement
The patients in this manuscript have given written informed consent to publication of their case details.

Conflict of interest
The authors have no conflicts of interest to declare.

Funding sources
This article has no funding source.

L. Juay,* N.S. Chandran
National University Hospital, Singapore, Singapore
*Correspondence: L. Juay, E-mail: lester_juay@nuhs.edu.sg

References
1 Shimabukuro T, Nair N. Allergic reactions including anaphylaxis after receipt of the first dose of Pfizer-BioNTech COVID-19 vaccine. JAMA 2021; 325: 780–781.
2 Blumenthal KG, Freeman EE, Saff RR et al. Delayed large local reactions to mRNA-1273 vaccine against SARS-CoV-2. N Engl J Med 2021; 384: 1273–1277.
3 Olesen AB, Juul S, Thestrup-Pedersen K. Atopic dermatitis is increased following vaccination for measles, mumps and rubella or measles infection. Acta Derm Venereol 2003; 83: 445–450.
4 Verheyden MJ, Bilgic A, Murrell DF. A Systematic Review of Drug-Induced Pemphigoid. Acta Derm Venereol 2020; 100: adv00224.
5 Rosenblatt AE, Stein SL. Cutaneous reactions to vaccinations. Clin Dermatol 2015; 33: 327–332.
6 Szatkowski J, Schwartz RA. Acute generalized exanthematous pustulosis (AGEP): a review and update. J Am Acad Dermatol 2015; 73: 843–848.
7 Zhang H, Chen X, Li J, Xie HF. Clinical analysis of childhood acute generalized exanthematous pustulosis. Zhongguo Dang Dai Er Ke Za Zhi 2008; 10: 497–499.
8 Matsuo S, Nishizawa A, Oshio-Yoshii A, Satoh T. Influenza vaccine-induced acute generalized exanthematous pustulosis during pregnancy. J Dermatol 2017; 44: 598–599.
9 McMahon DE, Amerson E, Rosenbach M et al. Cutaneous reactions reported after moderna and Pfizer COVID-19 vaccination: a registry-based study of 414 cases [published online ahead of print, 2021 Apr 7]. J Am Acad Dermatol 2021; 85: 45–55.

DOI: 10.1111/jdv.17581

Psoriasis exacerbation after COVID-19 vaccination: a report of 14 cases from a single centre

Editor,

High COVID-19 vaccination rates are a prerequisite for the establishment of herd immunity. Psoriasis patients seem to be more inclined to undergo COVID-19 vaccination, compared with matched controls suffering from other skin diseases and receiving immunosuppressive treatment (odds ratio, 1.32; 95% confidence interval: 1.28–1.36).1 Twenty-one per cent of 713 asked psoriasis patients declared fear of potential postvaccination flare of their skin disease to be holding them back from receiving a COVID-19 vaccine. Actual knowledge of the probability of this negative outcome occurring has largely been inadequate. As a number of vaccinated psoriasis patients steadily increase, the first data regarding this issue have been seeing the light of day.

Three European Medicines Agency-approved SARS-CoV-2 vaccines (Pfizer mRNA-BNT162b2; Moderna mRNA-1273; and AstraZeneca-Oxford AZD1222) have been administered to the Greek population from 27 December 2020 to 10 May 2021 (study lock date). Healthcare providers, followed by older individuals and those who were at the risk of severe COVID-19 infection due to comorbidities (including psoriasis under immunosuppressive treatment), were the first to be vaccinated in Greece.

Fourteen patients (mean age, 66.93; standard deviation, 9.68; females, 64.29%) (Table 1) presented to the emergency department of our hospital from 1 January to 10 May 2021 with sudden onset of a generalized papulosquamous rash, which was clinically diagnosed as psoriasis (Fig. 1). Of these, nine patients had had known mild psoriasis (mean duration, 16.39 years; standard deviation, 5.23), which had been left without treatment for over a year. Five patients had only been receiving topical treatment (steroids, calcipotriol/betamethasone), with which